Figure 2

Histopathological changes of liver of different experimental sub-groups. (A) Liver histopathology of rat of normal control group showed normal appearance(H &E, X 400), (B1) liver histopathology of MC sub-group showed severe steatosis (H&E, X400), (B2) liver histopathology of MC sub-group showed inflammatory cells collections of variable intensity (H&E, X400), (C) liver histopathology of atorvastatin treated sub-group showed relative decrease in hepatic steatosis intensity and surface area (H&E, X200), (D1) Liver histopathology of atorvastatin + nutraceutical 1 treated group: Liver showed much decrease in steatosis intensity and surface area than atorvastatin alone treated sub-group (H&E, X400), (D2) Liver histopathology of atorvastatin + nutraceutical 1 treated group: Liver showed excellent response in some rats with occasional fatty vacuoles (H&E, X400), (E) liver histopathology of rats treated with atorvastatin + nutraceutical 2, liver tissue with steatotic vacuoles in about 30% surface area (H&E, X400), (F1) liver histopathology of rats taken nutraceutical 1 only, some rats showed foamy vacuolated cytoplasm of the hepatocytes and some inflammation. (F2) Liver histopathology of rats taken nutraceutical 1 only, the hepatocytes of the rats had foamy cytoplasm with focal inflammatory cells but no steatosis (H&E, X400), (G) liver histopathology of rats taken nutraceutical 2 only, the hepatic steatosis was about 50% of the examined area.